Dexamethasone intravitreal implant (Aerie Pharmaceuticals)

地塞米松玻璃体内植入

Report date: 2026/05/20 20:02:01

Base Information

Drug NameDexamethasone intravitreal implant (Aerie Pharmaceuticals)
Drug Alias NameENV-1105AR-1105
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonists
TargetsGlucocorticoid receptor
Therapy Area/IndicationsDiabetic macular oedemaCoronavirus Disease 2019 (COVID-19)Blastic Plasmacytoid Dendritic Cell Neoplasm +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPuerto Rico +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAerie Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesWestern Institute for Veterans ResearchRothman Orthopaedic InstituteShandong University +[5] 
Inactive CompaniesWake Forest University Health SciencesAllergan PlcXi'An Jiaotong University Health Science Center +[7] 
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmChemotherapy-induced nausea and vomitingPain, Postoperative +[16] 
Inactive IndicationsDiabetic macular oedemaCoronavirus Disease 2019 (COVID-19)Psoriasis +[7] 

Other Information

ATC CodeN/A
Related LinksN/A